Some studies have focused on the use of EVs as treatments for CKD, but none to date have compared EVs derived from different sources (MSCs and expanded human umbilical cord blood (hUCB)-derived CD133+ cells (eCD133+)) under the same conditions. This evidence concerns the gene PROM1 and chronic kidney disease.